

# Karl Andersson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1984352/publications.pdf>

Version: 2024-02-01

55  
papers

1,848  
citations

279798

23  
h-index

276875

41  
g-index

55  
all docs

55  
docs citations

55  
times ranked

2157  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 1986-1992.	6.4	288
2	Radionuclide Therapy of HER2-Positive Microxenografts Using a <sup>177</sup> Lu-Labeled HER2-Specific Affibody Molecule. <i>Cancer Research</i> , 2007, 67, 2773-2782.	0.9	203
3	Biosensor Analysis of Drug-Target Interactions: Direct and Competitive Binding Assays for Investigation of Interactions between Thrombin and Thrombin Inhibitors. <i>Analytical Biochemistry</i> , 2000, 278, 1-13.	2.4	133
4	Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with <sup>125</sup> I-EGF. <i>PLoS ONE</i> , 2011, 6, e24739.	2.5	77
5	Kinetic determinations of molecular interactions using Biacore- minimum data requirements for efficient experimental design. <i>Journal of Molecular Recognition</i> , 2005, 18, 307-317.	2.1	75
6	Automated, high-resolution cellular retention and uptake studies in vitro. <i>Applied Radiation and Isotopes</i> , 2006, 64, 901-905.	1.5	70
7	[ <sup>177</sup> Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1457-1462.	6.4	61
8	Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells. <i>Frontiers in Immunology</i> , 2017, 8, 455.	4.8	51
9	Exploring buffer space for molecular interactions. , 1999, 12, 310-315.		50
10	Kinetic and Affinity Predictions of a Protein-Protein Interaction Using Multivariate Experimental Design. <i>Journal of Biological Chemistry</i> , 2002, 277, 29897-29907.	3.4	46
11	Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. <i>Applied Radiation and Isotopes</i> , 2006, 64, 32-37.	1.5	46
12	Comparing the Epidermal Growth Factor Interaction with Four Different Cell Lines: Intriguing Effects Imply Strong Dependency of Cellular Context. <i>PLoS ONE</i> , 2011, 6, e16536.	2.5	46
13	Methods for Radiolabelling of Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2014, 1060, 309-330.	0.9	40
14	[ <sup>99m</sup> Tc(CO) <sub>3</sub> ] <sup>+</sup> -(HE) <sub>3</sub> -ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 439-449.	6.4	38
15	Deciphering complex protein interaction kinetics using Interaction Map. <i>Biochemical and Biophysical Research Communications</i> , 2012, 428, 74-79.	2.1	37
16	Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. <i>Journal of Molecular Recognition</i> , 2001, 14, 62-71.	2.1	34
17	Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach. <i>Molecular and Clinical Oncology</i> , 2013, 1, 343-352.	1.0	32
18	<i>In Vivo</i> and <i>In Vitro</i> Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 187-195.	1.0	30

#	ARTICLE	IF	CITATIONS
19	QSAR studies applied to the prediction of antigen-antibody interaction kinetics as measured by BIACORE. <i>Protein Engineering, Design and Selection</i> , 2002, 15, 373-382.	2.1	29
20	The influence of Bz-DOTA and CHX- <sup>3</sup> -DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1460-1468.	6.4	27
21	Label-free kinetic binding data as a decisive element in drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2006, 1, 439-446.	5.0	26
22	Generation and Evaluation of Bispecific Affibody Molecules for Simultaneous Targeting of EGFR and HER2. <i>Bioconjugate Chemistry</i> , 2012, 23, 1802-1811.	3.6	26
23	Structural Modeling Extends QSAR Analysis of Antibody-Lysozyme Interactions to 3D-QSAR. <i>Biophysical Journal</i> , 2003, 84, 2264-2272.	0.5	25
24	Development of a rapid low cost fluorescent biosensor for the detection of food contaminants. <i>Biosensors and Bioelectronics</i> , 2013, 41, 96-102.	10.1	24
25	Characterization of <sup>111</sup> In and <sup>177</sup> Lu-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay. <i>Journal of Molecular Recognition</i> , 2008, 21, 179-183.	2.1	22
26	Impact of assay temperature on antibody binding characteristics in living cells: A case study. <i>Biomedical Reports</i> , 2017, 7, 400-406.	2.0	21
27	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. <i>International Journal of Oncology</i> , 2011, 40, 1677-82.	3.3	20
28	Real-time Monitoring using a breathalyzer-based eHealth system can identify lapse/relapse patterns in alcohol use disorder Patients. <i>Alcohol and Alcoholism</i> , 2018, 53, 368-375.	1.6	17
29	Characterizing and Controlling the Loading and Release of Cationic Amphiphilic Peptides onto and from PEG-Stabilized Lipodisks. <i>Langmuir</i> , 2016, 32, 12091-12099.	3.5	16
30	Thermodynamic and kinetic approaches for evaluation of monoclonal antibody - Lipoprotein interactions. <i>Analytical Biochemistry</i> , 2017, 518, 25-34.	2.4	16
31	Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. <i>Nuclear Medicine Communications</i> , 2011, 32, 863-867.	1.1	15
32	Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging. <i>Nuclear Medicine and Biology</i> , 2013, 40, 378-386.	0.6	15
33	Avidity characterization of genetically engineered T-cells with novel and established approaches. <i>BMC Immunology</i> , 2016, 17, 23.	2.2	15
34	Conjugation Effects on Antibody-Drug Conjugates: Evaluation of Interaction Kinetics in Real Time on Living Cells. <i>Molecular Pharmaceutics</i> , 2014, 11, 4154-4163.	4.6	14
35	Replacing affinity with binding kinetics in QSAR studies resolves otherwise confounded effects. <i>Journal of Chemometrics</i> , 2006, 20, 370-375.	1.3	13
36	Kinetic characterization of the interaction of the Z-fragment of protein A with mouse-IgG3 in a volume in chemical space. , 1999, 37, 494-498.		12

#	ARTICLE	IF	CITATIONS
37	Avoiding false negative results in specificity analysis of protein-protein interactions. <i>Journal of Molecular Recognition</i> , 2011, 24, 81-89.	2.1	12
38	Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods. <i>BMC Research Notes</i> , 2013, 6, 542.	1.4	12
39	Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 820-824.	2.1	11
40	Breathalyser-Based eHealth Data Suggest That Self-Reporting of Abstinence Is a Poor Outcome Measure for Alcohol Use Disorder Clinical Trials. <i>Alcohol and Alcoholism</i> , 2020, 55, 237-245.	1.6	11
41	Operator Dependent Choice of Prostate Cancer Biopsy Has Limited Impact on a Gene Signature Analysis for the Highly Expressed Genes IGFBP3 and F3 in Prostate Cancer Epithelial Cells. <i>PLoS ONE</i> , 2014, 9, e109610.	2.5	10
42	Exploring Time-Resolved Characterization of the Heterogeneity and Dynamics of Ligand-Receptor Interactions on Living Cells. <i>Journal of Analytical Oncology</i> , 2014, 3, .	0.1	9
43	Antibody-antigen interactions: What is the required time to equilibrium?. <i>Nature Precedings</i> , 2010, , .	0.1	8
44	Automated functional characterization of radiolabeled antibodies. <i>Nuclear Medicine Communications</i> , 2014, 35, 767-776.	1.1	8
45	Deciphering the Stepwise Binding Mode of HRG1 <sup>2</sup> to HER3 by Surface Plasmon Resonance and Interaction Map. <i>PLoS ONE</i> , 2015, 10, e0116870.	2.5	8
46	Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. <i>PLoS ONE</i> , 2016, 11, e0145545.	2.5	8
47	Novel Real-Time Proximity Assay for Characterizing Multiple Receptor Interactions on Living Cells. <i>Analytical Chemistry</i> , 2017, 89, 13212-13218.	6.5	8
48	Real-time viability assay based on <sup>51</sup> Cr retention in adherent cells. <i>BioTechniques</i> , 2008, 44, 237-240.	1.8	7
49	Real-time immunohistochemistry analysis of embedded tissue. <i>Applied Radiation and Isotopes</i> , 2010, 68, 2372-2376.	1.5	6
50	Maximum Time Between Tests: A Digital Biomarker to Detect Therapy Compliance and Assess Schedule Quality in Measurement-Based eHealth Systems for Alcohol Use Disorder. <i>Alcohol and Alcoholism</i> , 2019, 54, 70-72.	1.6	6
51	The Clinical Course of Alcohol Use Disorder Depicted by Digital Biomarkers. <i>Frontiers in Digital Health</i> , 2021, 3, 732049.	2.8	4
52	Evaluation of Real-Time Immunohistochemistry and Interaction Map as an Alternative Objective Assessment of HER2 Expression in Human Breast Cancer Tissue. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 497-505.	1.2	3
53	Detecting ligand interactions in real time on living bacterial cells. <i>Applied Microbiology and Biotechnology</i> , 2018, 102, 4193-4201.	3.6	3
54	Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay. <i>Journal of Pharmacological and Toxicological Methods</i> , 2014, 70, 145-151.	0.7	2

#	ARTICLE	IF	CITATIONS
55	A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells. FEBS Letters, 2020, 594, 2406-2420.	2.8	2